About: Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old
Creator	Mulligan, Mark Thornburg, Natalie Rouphael, Nadine Mcneal, Monica Bangaru, Sandhya Keitel, Wendy Jackson, Lisa Bellamy, Abbie Hill, Heather Lai, Lilin Patel, Shital Winokur, Patricia
source	PMC
abstract	BACKGROUND: Variant influenza A(H3N2) viruses (H3N2v) have transmitted recently from pigs to humans in the United States. Vaccines strategies are needed. METHODS: Healthy adults received 2 doses of subvirion H3N2v vaccine (15 µg of hemagglutinin/dose) 21 days apart in this open-label trial. Serum hemagglutination inhibition (HAI) and neutralizing (Neut) antibody (Ab) titers were measured before and 8 and 21 days after each dose. Memory B-cell (MBC) responses were assessed. RESULTS: Vaccine was well tolerated. A total of 40% of subjects had an HAI Ab titer of ≥40 before vaccination. Eight-seven percent (95% confidence interval [CI], 79%–93%) and 73% (95% CI, 63%–81%) of subjects 18–64 years old (98 subjects) and ≥65 years old (90 subjects), respectively, had an HAI titer of ≥40 21 days after dose 1 (P = .01); 51% (95% CI, 41%–61%) and 52% (95% CI, 41%–62%) of younger and older subjects, respectively, developed ≥4-fold rises in titer (P = not significant). Neut Ab response patterns were similar. Geometric mean titers were higher in younger subjects. Dose 2 provided no significant enhancement in responses. Cross-reactive MBCs were detected before vaccination and expanded after vaccination. Preexisting H3N2v-specific MBCs positively correlated with early increases in vaccine-induced Ab. CONCLUSIONS: In most healthy adults, one 15-µg dose of vaccine elicited levels of HAI Abs associated with protection. Studies in children and elderly individuals are indicated to define the immunization needs of these groups. CLINICAL TRIALS REGISTRATION: NCT01746082.
has issue date	2015-08-15(xsd:dateTime)
bibo:doi	10.1093/infdis/jiv056
bibo:pmid	25649171
has license	no-cc
sha1sum (hex)	9e602f46961cce9ac77ee54f6f478362153510b3
schema:url	https://doi.org/10.1093/infdis/jiv056
resource representing a document's title	Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old
has PubMed Central identifier	PMC4539893
has PubMed identifier	25649171
schema:publication	J Infect Dis
resource representing a document's body	covid:9e602f46961cce9ac77ee54f6f478362153510b3#body_text
is schema:about of	named entity 'NEEDED' named entity 'United States' named entity 'needed' named entity 'H3N2' named entity 'influenza' named entity 'Vaccine' named entity 'titer' named entity 'Recombinant' named entity 'IgG' named entity 'MBCs' named entity 'peripheral blood mononuclear cells' named entity 'serum' named entity 'Biodefense' named entity 'Millipore' named entity 'Vaccine' named entity 'transfection' named entity 'vaccine' named entity 'infection' named entity 'subcloned' named entity 'histidine' named entity 'vaccine' named entity 'immunization' named entity 'Protein' named entity 'infection' named entity 'MBCs' named entity 'viruses' named entity 'informed consent' named entity 'immune responses' named entity 'serum' named entity 'Immune responses' named entity 'seroconversion' named entity 'H3N2v' named entity 'H3N2' named entity 'H3N2v' named entity 'influenza vaccine' named entity 'cross-react' named entity 'microtiter plates' named entity 'PBMCs' named entity 'titer' named entity 'SAEs' named entity 'Immunogenicity' named entity 'titer' named entity 'H3N2' named entity 'titer' named entity 'generalized least squares' named entity 'mitogens' named entity 'vaccine' named entity 'liquid nitrogen' named entity 'Victoria' named entity 'vaccination' named entity 'immunization' named entity 'correlation' named entity 'H3N2' named entity 'tested for the presence' named entity 'hemagglutination inhibition' named entity 'plasma cells' named entity 'clinical trial' named entity 'Staphylococcus aureus' named entity 'MBCs' named entity 'MBCs' named entity 'pandemic influenza' named entity 'ELISpot' named entity 'Sanofi Pasteur' named entity 'H3N2' named entity 'influenza' named entity 'vaccination' named entity 'H3N2' named entity 'MBC' named entity 'vaccine strain' named entity 'linear regression'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software